Treatment of ringworm infections of skin with terbinafine

Response to terbinafine in cutaneous tinea infections

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/05/008687

Enrollment

500

Registered

2017-05-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Tinea corporis, tinea cruris, tinea manuum, tinea pedis

Interventions

Intervention1: Terbinafine: 1. Terbinafine dose: 5mg/kg body weight/day orally for 4 weeks 2. Patients will also apply topical Terbinafine (1%) cream twice daily for 4 weeks Control Intervention1: Not

Eligibility

Inclusion criteria

Inclusion criteria: Patients with tinea corporis, tinea cruris, tinea manuum and tinea pedis who show fungal elements on KOH microscopy of skin scrapings

Exclusion criteria

Exclusion criteria: 1. Use of terbinafine (oral or topical) in past 1 week 2. Pregnancy or lactation 3. Past history of drug reaction to terbinafine (oral or topical) 4. Concurrent hepatic or renal disease as stated by the patient 5. Inability of the patient to come for follow up

Design outcomes

Primary

Measure	Time frame
Complete clearance of lesions and negative KOH microscopyTimepoint: 0, 2, 4 weeks. Cured patients reviewed after 1 month of completion of treatment and assessed for reappearance of leions	—

Secondary

Measure	Time frame
NoneTimepoint: 0	—

Countries

India

Contacts

Public ContactPrakriti Shukla

Institute of Medical Sciences, Banaras Hindu University

sanjaye2@gmail.com05422309488

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026